Every Form 4 that Exelixis Inc (EXEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EXEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXEL filings page.
EXELIXIS, INC. director Mary C. Beckerle reported selling 9,812 shares of Common Stock on August 10, 2026 in an open-market transaction at a weighted average price of $53.66 per share, with individual trade prices ranging from $53.16 to $54.02.
After this sale, Beckerle’s reported holdings consist of 16,079 shares, all to be issued upon vesting of restricted stock units, each RSU being the economic equivalent of one share of Common Stock. The sale was executed under a Rule 10b5-1 trading plan adopted on May 8, 2026.
EXELIXIS, INC. director Jack L. Wyszomierski reported an open-market sale of 3,925 shares of common stock at $50.55 per share. The transaction was executed on June 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 284,384 shares of Exelixis common stock, and the filing notes an additional 8,367 shares that will be delivered upon vesting of restricted stock units.
EXELIXIS, INC. director Sue Gail Eckhardt reported an open-market sale of 9,812 shares of Common Stock at a weighted average price of $50.14 per share on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
After this transaction, her reported holdings total 16,079 shares of Common Stock, including shares that will be issued upon vesting of restricted stock units, with each unit economically equivalent to one share.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Stelios Papadopoulos received an equity award in the form of 8,367 restricted stock units, each equivalent to one share of common stock. The grant was made at no cash cost to him.
The RSUs are scheduled to vest 100% on May 27, 2027, provided he remains in continuous service through that date. After this award, his direct holdings reported in this filing total 1,197,595 shares of common stock, including the shares underlying the RSUs.
Heyman Tomas J. reported acquisition or exercise transactions in this Form 4 filing.
Exelixis director Tomas J. Heyman received a new equity award. He was granted 8,367 restricted stock units (RSUs) of Exelixis common stock on May 27, 2026 under the 2017 Equity Incentive Plan, with no cash paid per share.
Each RSU equals one share of common stock and will vest 100% on May 27, 2027, if he continues serving through that date. After this grant, Heyman holds 50,649 shares in total, including 17,455 shares that will be issued when previously granted RSUs vest.
Eckhardt Sue Gail reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Sue Gail Eckhardt received a grant of 8,367 restricted stock units on May 27, 2026 under the company’s 2017 Equity Incentive Plan. Each RSU represents one share of common stock and will vest in full on May 27, 2027 if she remains in continuous service. Following this award, she holds 25,891 shares of common stock, including 16,079 shares that will be issued upon vesting of outstanding RSUs.
Smith Julie reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Julie Smith reported an equity compensation grant of 8,367 restricted stock units on May 27, 2026. The award carries no purchase price and each unit is economically equivalent to one share of common stock.
The RSUs will vest in full on May 27, 2027, provided she remains in continuous service through that date. Following this grant, Smith is shown as holding 28,957 shares of common stock, including the shares that will be issued upon vesting of these RSUs.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Maria C. Freire received a grant of 8,367 restricted stock units (RSUs) on May 27, 2026 under the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU equals one share of common stock and will vest 100% on May 27, 2027, subject to her continuous service. After this award, she directly holds 109,186 shares of common stock, including the shares underlying these RSUs.
Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Mary C. Beckerle received a grant of 8,367 restricted stock units (RSUs), each equal to one share of common stock. The award was granted under the 2017 Equity Incentive Plan and will vest in full on May 27, 2027, subject to continuous service. Following this grant, she holds 25,891 shares and RSUs, including 16,079 shares issuable upon future RSU vesting.
Oliver Bob reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Oliver Bob received a grant of 8,367 shares of Common Stock in the form of restricted stock units as compensation. The RSUs were granted at no cash cost and will vest in full on May 27, 2027, if he remains in continuous service. After this award, he directly holds 29,487 shares, including 17,455 shares that will be issued upon vesting of existing RSUs.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
Exelixis, Inc. director Jack L. Wyszomierski received a grant of 8,367 restricted stock units, each equal to one share of common stock, under the 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to continuous service, bringing his reported holdings to 288,309 shares.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director George Poste received a grant of 8,367 restricted stock units, each equal to one share of common stock and granted at no cost, under the company’s 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to his continuous service. After this award, he directly beneficially owns 127,199 shares of common stock, including the unvested RSUs.
EXELIXIS, INC. director David Edward Johnson reported receiving an option grant covering 19,133 shares of common stock. The option has an exercise price of $50.03 per share, is exercisable immediately subject to repurchase provisions, and expires on May 26, 2033. It will vest in full on the first anniversary of the grant date, conditioned on Mr. Johnson’s continuous service. After this award, he holds options for 19,133 shares. Footnotes state the securities are deemed held for the benefit of Caligan Partners Master Fund LP and certain managed accounts of Caligan Partners LP, and may be transferred to those entities after vesting.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported an open-market sale of Common Stock. On May 26, 2026, Aftab sold 43,451 shares of Exelixis common stock at $50.35 per share.
After this transaction, Aftab directly holds 594,741 shares of common stock. In addition, a separate entry shows 5,835 shares held indirectly through the Exelixis 401(k) Plan. Footnotes also note 405,966 shares that may be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.
Exelixis, Inc. executive Patrick J. Haley reported an open‑market sale of 32,110 shares of Common Stock. The shares were sold at a weighted average price of $49.81 per share, with individual trades ranging from $49.80 to $49.89.
After this transaction, Haley directly holds 357,638 shares of Exelixis common stock. Footnote disclosure states that this figure includes 356,992 shares that will be issued upon vesting of restricted stock units and a performance-based restricted stock unit award, each convertible into one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported non-market share dispositions consisting of tax withholding and bona fide gifts of common stock. On May 15, 2026, 128,497 shares were withheld at $51.10 per share to satisfy taxes tied to the vesting of restricted stock units awarded between 2022 and 2025.
On May 18, 2026, he made two bona fide gifts of 124,047 shares each, one from direct holdings and one involving the Morrissey Family Living Trust, for a total of 248,094 gifted shares at no consideration. After these transactions, filings show 1,362,008 shares associated with RSUs and performance-based awards, 2,004,327 shares held by the family trust, and 17,728 shares in the company 401(k) plan.
Exelixis, Inc. EVP and CFO Christopher J. Senner reported an open‑market sale of 34,901 shares of common stock at a weighted average price of $50.00 per share. The sale was executed as a standard market transaction.
In a separate non‑market event, 40,892 shares were withheld by Exelixis to cover taxes on vesting of previously granted restricted stock units at $51.10 per share. Following these transactions, Senner directly owns 952,317 shares of Exelixis common stock and indirectly holds 2,723 shares through the company’s 401(k) plan. Footnotes also state that 403,915 additional shares are subject to unvested RSUs and performance-based awards that may be issued upon future vesting.
EXELIXIS, INC. executive Patrick J. Haley, EVP, Commercial, reported a tax-related share withholding tied to vesting of prior equity awards. On the transaction date, the company withheld 33,265 shares of common stock at $51.10 per share to satisfy tax obligations on vested RSUs. Following this non-market disposition, Haley reported ownership of 389,748 shares of Exelixis common stock. This figure includes 356,992 shares that will be issued upon vesting of RSUs and a performance-based restricted stock unit award, plus 646 shares acquired through the Exelixis Employee Stock Purchase Plan.
Exelixis, Inc. SVP and General Counsel Brenda Hefti reported an open-market sale of 6,625 shares of common stock at a weighted average price of $50.21 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
Separately, 6,411 shares were withheld by Exelixis to cover taxes due on the vesting of restricted stock units granted in 2022, 2024, and 2025. After these transactions, she holds 106,762 shares directly and 5,527 shares indirectly through the Exelixis 401(k) Plan.
Her holdings include 106,039 shares that will be issued upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025, plus 167 shares acquired on April 30, 2026 through the Exelixis 2000 Employee Stock Purchase Plan.
Exelixis EVP Dana Aftab reported routine share activity tied to equity compensation. On the Form 4, 30,578 shares of common stock were withheld by Exelixis at a price of $51.10 per share to cover taxes due upon vesting of previously granted restricted stock units.
After this tax-withholding disposition, Aftab holds 638,192 shares of Exelixis common stock directly, plus 5,835 shares indirectly through the company’s 401(k) plan. Footnotes also note additional unvested RSUs and performance-based stock units that may convert into common shares over time.
EXELIXIS, INC. director Mary C. Beckerle reported an exercise-and-sell transaction in company stock. She sold 7,712 shares of common stock in an open-market sale at $48.45 per share. She also exercised options to acquire 3,856 shares at an exercise price of $23.24 per share. Following these transactions, she holds 25,236 shares of common stock, including 17,524 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Maria C. Freire reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised options to acquire 20,634 shares of Common Stock at $19.77 per share, then sold 20,634 shares in an open-market sale at $46.00 per share.
After these transactions, she directly holds 100,819 shares of Common Stock, which include 9,812 shares that will be issued upon vesting of restricted stock units. The option exercised covered 20,634 shares, became fully exercisable on May 23, 2019, and now has no remaining balance.
EXELIXIS, INC. director George Poste reported an open-market sale of 60,000 shares of common stock on May 7, 2026 at a weighted average price of $45.71 per share. The transactions were executed in multiple trades between $45.65 and $45.85 per share.
Following the sale, Poste directly holds 118,832 shares of Exelixis common stock, which includes 9,812 shares that will be issued upon vesting of restricted stock units (RSUs). Each RSU represents the economic equivalent of one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported a charitable stock transfer and updated holdings. On May 6, 2026, he made a bona fide gift of 109,676 shares of Exelixis common stock to the Bombora Rise Foundation through the Morrissey Family Living Trust, which then held 1,880,280 shares indirectly. He is also shown with 1,614,552 shares of common stock that will be issued upon vesting of restricted stock units and performance-based awards, plus 17,728 shares held through the Exelixis 401(k) Plan.
Aftab Dana reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an equity compensation grant in the form of restricted stock units (RSUs). The award covers 52,018 shares of common stock, granted under the company’s 2017 Equity Incentive Plan at no cash cost.
These RSUs will vest as to one quarter of the original grant on May 15, 2027, and one quarter on each following May 15 until fully vested. Following this grant, Aftab’s directly held common stock position, including previously granted RSUs and performance-based RSUs, totals 668,124 shares, of which 466,061 shares relate to unvested RSUs and a prior performance-based award. In addition, 5,835 shares are held indirectly through the Exelixis 401(k) Plan as of a statement dated February 26, 2026.
EXELIXIS, INC. Executive Vice President and CFO Christopher J. Senner reported an equity compensation award in the form of restricted stock units tied to the company’s common stock. The filing shows an acquisition of 52,018 shares of common stock at a price of $0.00 per share, representing RSUs granted under the Exelixis, Inc. 2017 Equity Incentive Plan that will be issued upon vesting. These RSUs vest in four equal annual installments, beginning May 15, 2027 and then each May 15 thereafter until fully vested. After this grant, Senner directly owns or has rights to 1,028,110 shares of common stock, including 479,708 shares that will be issued upon vesting of previously granted RSUs and performance-based restricted stock units. He also indirectly holds 2,723 shares through the Exelixis, Inc. 401(k) Plan as of February 26, 2026.
Hefti Brenda reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti received an equity award in the form of restricted stock units (RSUs) tied to the company’s common stock. The grant covers 23,119 shares that will be issued as the RSUs vest over time.
According to the grant terms, one-quarter of the original RSU amount will vest on May 15, 2027, with additional one-quarter installments vesting on each May 15 thereafter until fully vested. Following this award, Hefti has 119,631 shares of common stock reported as directly owned, including shares underlying previously granted RSUs and performance-based restricted stock units, and 5,527 shares held indirectly through the company’s 401(k) plan.
Haley Patrick J. reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive Patrick J. Haley, EVP, Commercial, received an equity grant of 40,459 restricted stock units (RSUs) of common stock. The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan and carry no purchase price.
The award will vest as to one-quarter of the original RSU share amount on May 15, 2027, and one-quarter on each May 15 thereafter until fully vested. Following this grant, a total of 422,367 shares of common stock are scheduled to be issued to Haley upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
EXELIXIS, INC. President and CEO Michael Morrissey reported both an equity award and a charitable gift of company stock. On February 26, 2026, he was granted 160,437 restricted stock units (RSUs) under the Exelixis, Inc. 2017 Equity Incentive Plan at no cash cost.
The RSUs will vest as to one-quarter of the original shares on May 15, 2027 and then one-quarter on each May 15 thereafter until fully vested. Following this grant, 1,614,552 shares of common stock are scheduled to be issued to him upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
Separately, on February 24, 2026, shares held by the Morrissey Family Living Trust were used to make a bona fide gift of 100,278 shares of Exelixis common stock to the Bombora Rise Foundation. In addition, 17,728 shares are held for his benefit under the Exelixis, Inc. 401(k) Plan as of February 26, 2026.
Exelixis EVP of Research and Development Dana Aftab reported an open-market sale of 47,918 shares of common stock at $44.50 per share. After this sale, Aftab directly holds 616,106 shares, which include 414,043 shares tied to unvested RSUs and PSUs.
Aftab also indirectly holds 5,835 shares through the Exelixis 401(k) plan, based on a statement dated February 23, 2026.
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an open-market sale of 29,873 shares of common stock on February 19, 2026 at a price of $44.35 per share. After this sale, Aftab directly holds 664,024 shares of Exelixis common stock.
In addition, Aftab has an indirect holding of 5,835 shares through the Exelixis 401(k) Plan based on a statement dated February 18, 2026. Footnotes also state that 414,043 shares are scheduled to be issued upon vesting of previously granted RSUs and performance stock units.
Exelixis, Inc. director Jack L. Wyszomierski reported option exercises and share sales. On February 18, 2026, he exercised an option for 20,634 shares of common stock, converting an "Option (right to buy)" that had become fully exercisable on May 23, 2019.
On the same date, he sold 99,574 shares of Exelixis common stock at a weighted average price of $44.01 per share, in multiple trades ranging from $43.32 to $44.49, under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 279,942 shares of common stock, including 9,812 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Julie Smith reported combined option exercises and stock sales. On February 17–18, 2026, she exercised options covering a total of 106,539 shares of common stock at exercise prices of $18.19, $19.39 and $21.69 per share.
Over the same two days she sold 106,539 shares of Exelixis common stock in open-market transactions at prices including $43.33, $44.30 and $44.50 per share, resulting in a net sale position. After these trades she directly owned 20,590 shares of common stock, and a footnote states she also holds 9,812 restricted stock units that will settle into common shares upon vesting.
Exelixis, Inc. executive Christopher J. Senner, EVP and CFO, reported net stock sales. On February 13 and 17, 2026, he executed open‑market sales of Exelixis common stock totaling 64,895 shares at prices around $43–$44 per share.
On February 15, 2026, an additional 35,870 shares were disposed of to cover taxes due on previously granted performance‑based restricted stock units, rather than sold for cash. After these transactions, he directly owned 976,092 shares, which include 427,690 shares underlying RSUs and performance stock units, and indirectly held 2,723 shares through the Exelixis 401(k) plan.
Exelixis, Inc. executive Patrick J. Haley, EVP Commercial, reported significant insider share activity. On February 17, 2026, he executed two open-market sales of Exelixis common stock totaling 67,814 shares, with 3,036 shares sold at $43.84 per share and 64,778 shares sold at $43.50 per share.
On February 15, 2026, 31,483 shares were disposed of to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022, after performance criteria were certified on January 16, 2025. Following these transactions, Haley holds 381,908 shares, a figure that includes restricted stock units and performance stock units granted on March 31, 2025, each representing or economically equivalent to one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported multiple equity transactions in company common stock. He exercised an option for 494,700 shares on February 13, 2026 at a stated exercise price of $21.31 per share, increasing his direct holdings.
To cover the option exercise price and related taxes, 369,606 shares were withheld at $43.92 per share, and a further 120,390 shares were withheld on February 15, 2026 to satisfy tax liabilities after performance-based restricted stock units vested. Morrissey also made bona fide gifts totaling 501,472 shares over February 17–18, 2026, transferring shares to the Morrissey Family Trust, which holds shares as trustees.
A footnote states that 1,454,115 shares of common stock will be issued upon vesting of previously granted RSUs and performance stock units, each representing the right to receive one share of common stock.
Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share. The transaction was executed under a prearranged Rule 10b5-1 trading plan adopted on November 11, 2025. After this sale, she beneficially owns 17,524 shares, including shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported two tax-related share dispositions. On February 15, 2026, a total of 26,485 and 12,720 shares of common stock were withheld at $43.92 per share to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022 and restricted stock units granted on January 5, 2023. These are tax-withholding dispositions, not open-market sales. After these transactions, Aftab directly holds 693,897 shares of common stock, which include 414,043 shares underlying restricted stock units and performance stock units granted on March 31, 2025. In addition, there are 5,835 shares held indirectly through the Exelixis 401(k) Plan as of February 13, 2026.
Exelixis, Inc. director Bob Oliver reported mixed activity in company stock. On February 13, 2026, he sold 9,088 shares of common stock in an open-market transaction at $43.61 per share and separately sold 21,162 shares at a weighted average price of $43.90 per share, with individual trades between $43.90 and $43.96 as noted in a footnote.
On the same date, he exercised an option for 9,088 shares of common stock, recorded as both a derivative exercise and an acquisition of common shares at an exercise price of $19.28 per share. A footnote states this option originally covered 36,353 shares and became fully exercisable on May 31, 2023. Another footnote notes 18,900 restricted stock units that will convert into common shares upon vesting.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti reported insider transactions in company common stock. She sold 18,669 shares in an open-market sale at an average price of $44.01 per share under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,430 shares were withheld by the company to cover taxes due on the vesting of performance-based restricted stock units. After these transactions, she continued to hold a substantial direct equity position, along with additional restricted stock units, performance stock units expected to deliver 95,956 shares upon vesting, and 5,527 shares held indirectly through the company’s 401(k) plan.
Exelixis, Inc. President and CEO Michael Morrissey reported equity compensation activity involving company common stock. On January 15, 2026, he acquired 548,073 shares of common stock at $0 per share through the vesting of a performance-based restricted stock unit award. On the same date, 139,524 shares were withheld at $45.23 per share to cover taxes related to this vesting.
After these transactions, Morrissey held 1,825,241 shares of Exelixis common stock directly. In addition, 1,714,404 shares were held indirectly by the Morrissey Family Living Trust, and 17,728 shares were held indirectly through the Exelixis 401(k) Plan. A separate grant includes 1,690,729 shares that may be issued in the future upon vesting of restricted stock units and performance-based units previously awarded.
Exelixis, Inc. executive Aftab Dana, EVP of Research and Development, reported equity award activity tied to a performance-based restricted stock unit (PSU) grant. On January 15, 2026, 119,578 shares of common stock were acquired at $0 per share upon certification that certain PSU performance criteria were achieved. On the same date, 27,254 shares were withheld at $45.23 per share to cover taxes from this vesting. After these transactions, Dana beneficially owned 733,102 shares of Exelixis common stock directly, which includes 491,096 shares that will be issued upon future vesting of restricted stock units and PSUs granted on March 31, 2025, and also held 5,835 shares indirectly through the Exelixis 401(k) Plan as of January 14, 2026.
Exelixis, Inc. EVP, Commercial Haley J. Patrick reported equity award activity tied to performance-based restricted stock units. On January 15, 2026, 139,508 shares of common stock were acquired at $0 per share upon vesting of a performance-based restricted stock unit award originally granted on April 3, 2023, following the Compensation Committee’s certification that certain performance criteria had been achieved.
On the same date, 32,332 shares were withheld at a price of $45.23 per share to cover taxes related to this PSU vesting. After these transactions, Patrick directly beneficially owned 481,205 shares of Exelixis common stock, which includes 443,784 shares that will be issued upon future vesting of previously granted RSUs and one-time performance stock units awarded on March 31, 2025.
Exelixis, Inc. EVP and CFO Christopher J. Senner reported equity award activity on January 15, 2026. He acquired 149,474 shares of common stock at $0 per share upon vesting of performance-based restricted stock units granted on April 3, 2023, after the compensation committee certified achievement of required performance criteria.
To cover taxes related to this vesting, 40,459 shares were withheld by Exelixis at a price of $45.23 per share. After these transactions, Senner directly beneficially owns 1,076,857 shares of Exelixis common stock, which include 494,177 shares that will be issued upon future vesting of previously granted RSUs and PSUs. He also indirectly holds 2,723 shares through the Exelixis 401(k) plan as of January 14, 2026.
Exelixis, Inc. (EXEL) director David Johnson, together with Caligan Partners LP, reported an open-market purchase of 27,532 shares of common stock on 11/25/2025 at a price of $43.122 per share. After this transaction, 1,553,262 shares are reported as indirectly owned through Caligan-managed funds and accounts, while 18,176 shares are reported separately, which include 9,088 shares that will be issued upon vesting of restricted stock units to Johnson. The reporting persons state they disclaim beneficial ownership of the securities beyond any pecuniary interest and note that Caligan may be deemed a director by deputization because Johnson serves on the Exelixis board.
Exelixis, Inc. executive reports insider stock sales. The company’s EVP, Commercial, filed a Form 4 showing sales of a total of 72,230 shares of Exelixis common stock on November 20–21, 2025.
On November 20, 2025, the executive sold 10,000 shares at a weighted average price of $42.11, while a spouse’s account sold 23,539 shares at a weighted average price of $41.93, and a 401(k) account sold 10,648 shares at a weighted average price of $41.77. On November 21, 2025, the executive sold 28,043 shares at a weighted average price of $42.58.
Following these transactions, the executive beneficially owns 374,029 shares, consisting of Exelixis common stock that will be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.
Exelixis, Inc. (EXEL) reported an insider stock gift by a senior executive. The company’s EVP of Research and Development filed a Form 4 disclosing that on November 21, 2025, they gifted 24,000 shares of Exelixis common stock to a donor-advised fund at a reported price of $0, reflecting a charitable transfer rather than a market sale.
After this gift, the executive beneficially owned 640,778 shares directly, which includes 431,306 shares of common stock scheduled to be issued upon vesting of restricted stock units and performance-based restricted stock units. The filing also shows 5,835 shares held indirectly through the Exelixis, Inc. 401(k) Plan based on a plan statement dated November 20, 2025.
Exelixis, Inc. (EXEL) director reports stock gift. A company director reported gifting 1,044 shares of Exelixis common stock on 11/17/2025 to a not-for-profit organization. The transaction was coded as a gift with a reported price of $0, reflecting that it was not a sale. After this transfer, the reporting person beneficially owns 42,282 shares of Exelixis common stock, including 18,900 shares that will be issued upon vesting of restricted stock units, where each RSU represents one share of common stock.
Exelixis, Inc. director filed a Form 4 reporting the sale of 100,000 shares of common stock on 11/12/2025 at a $43.55 weighted average price, with sales executed between $43.55 and $43.58.
After the transaction, the reporting person beneficially owned 1,189,228 shares directly. This amount includes 9,812 RSUs, each representing the right to receive one share upon vesting.
Exelixis (EXEL) President and CEO Michael M. Morrissey filed a Form 4 reporting charitable and estate-planning stock transfers. On 11/11/2025, he gifted 160,000 shares of common stock to the Bombora Rise Foundation. On 11/12/2025, he gifted 101,548 shares to the Morrissey Family Living Trust and 80,000 shares to a donor advised fund. All gifts were at a reported price of $0 per share (transaction code G).
Following these transactions, the filing shows 1,714,404 shares held by the Morrissey Family Living Trust and 17,728 shares held via the Exelixis 401(k) Plan. It also notes 1,416,692 shares that will be issued upon vesting of RSUs and PSUs, each representing one share of common stock.